Company: DAWN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0000950170-25-026654
Chunk: 355

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 7
Chunk 355
---
 other current liabilities of $42.1 million, deferred revenue of $4.8 million, accounts payable of $0.7 million, other long-term liability of $0.8 million, and a decrease in deposits and other long-term assets of $0.1 million. This was partially offset by an increase in accounts receivable of $13.9 million, prepaid expenses and other current assets of $4.6 million, inventory of $3.2 million, and a decrease of operating lease liabilities of $0.3 million.

Net cash used in operating activities for the year ended December 31, 2023 was $146.9 million, consisting of our net loss of $188.9 million, changes of approximately $9.5 million in net operating assets and liabilities and by non-cash charges of $32.6 million, which is primarily comprised of share-based compensation expense of $39.3 million. Changes in operating assets and liabilities were primarily related to an increase in accrued expenses and other current liabilities of $10.6 million and accounts payable of $2.3 million and a decrease in deposits and other long-term assets of $0.3 million. This was partially offset by an increase of prepaid expenses and other current assets of $3.3 million and a decrease of operating lease liabilities of $0.4 million.

Investing activities 

Net cash used in investing activities for the year ended December 31, 2024 was $231.0 million attributable to the purchase of short-term investments of $658.6 million, acquisition of in-process research and development assets of $55.0 million, acquisition of intangible assets of $17.1 million, and the purchase of property and equipment of $2.2 million. This was partially offset by the proceeds from maturity of short-term investments of $314.5 million, the sale of the PRV of $108.0 million, and the sale of short-term investments of $79.4 million. 

Net cash provided by investing activities for the year ended December 31, 2023 was $128.4 million attributable to the proceeds from the maturity of short-term investments of $575.4 million. This was partially offset by the purchase of short-term investments of $443.8 million, cash paid for acquired in-process research and development assets of $3.0 million, and cash paid for the purchase of property and equipment of $0.2 million.

Financing activities 

Cash provided by financing activities for the year December 31